Fangzhou and Tenry Pharmaceutical Partner on AI-Powered Diabetes Care
Fangzhou Inc., a Hong Kong-listed chronic disease management platform, and Shanghai Tenry Pharmaceutical have formed a strategic partnership to integrate AI tools with drug treatment for type 2 diabetes and metabolic disorders.
The collaboration, announced at the 92nd PHARMCHINA conference in Shanghai on May 14, will bring Tenry's GLP-1 therapy Paidakang® (vipeglutide) onto Fangzhou's Internet hospital platform for nationwide distribution. Fangzhou operates 56.4 million registered user accounts and works with 251,000 physicians.
How the Partnership Works
Fangzhou will apply its AI tools-including an AI Medication Assistant, AI Doctor Assistant, and AI Health Manager-to support patient care around Paidakang®. These tools run on the company's proprietary Xingshi Large Language Model.
The approach shifts the model from medication supply alone to broader patient support across the treatment journey. Patients will access both the drug and digital health management through Fangzhou's "AI+H2H (Hospital to Home)" model, which connects hospital care to home-based monitoring.
The Drug
Paidakang® achieved sustained blood glucose control over 52 weeks in clinical trials with lower gastrointestinal side effects than competing GLP-1 therapies. The drug requires no dose titration, simplifying the treatment regimen.
Tenry Pharmaceutical secured exclusive commercialization rights for Paidakang® in mainland China in March 2026. The drug was developed by PegBio Co., Ltd.
What's Next
Both companies plan to expand AI applications and explore additional service scenarios under what they call the "AI+Chronic Disease Service" model. The partnership aligns with China's Healthy China 2030 initiative.
For healthcare professionals, this represents a shift in how chronic disease platforms integrate drug therapies with digital care tools. The model demonstrates one approach to scaling personalized treatment across a large patient population.
Learn more: AI for Healthcare and Generative AI and LLM resources cover the technologies underlying these platforms.
Your membership also unlocks:
